Press "Enter" to skip to content

Vascular Biogenics' Ovarian Cancer Gene Therapy Study To Continue, Recommends An Independent Committee

  • Vascular Biogenics Ltd (NASDAQ: VBLTannounces results from the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 study of VB-111 in recurrent ovarian cancer.
  • According to the results, the committee found no safety issues with the trial and recommended its continuation.
  • The following DSMC review is scheduled for the third quarter of 2021, followed by completion of enrollment at the end of 2021 or in early 2022
  • In March last year, interim analysis in the OVAL study demonstrated an overall response rate of 53%. The response rate in the treatment arm (VB-111 in addition to weekly paclitaxel) was at least 10% higher than in the control arm. According to the Company update in November, a high response rate of greater than 50% in the total evaluable patient population was maintained with approximately 200 patients enrolled.
  • VB-111 (ofranergene obadenovec) is an investigational targeted anti-cancer gene-therapy that uses a dual mechanism to target solid tumors. Its mechanism combines the blockade of tumor vasculature with an anti-tumor immune response. VB-111 is administered as an IV infusion once every 6-8 weeks.
  • Price Action: VBLT is up 5.29% at $2.42 in market trading hours on the last check Monday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *